For decades, markets rewarded management teams that could master a strategy, stick to it, and talk about it in perfect bullet points. Today, investors are quietly rerating a different skill: the ability to discard that strategy on demand when the world—and the…
Hims & Hers (HIMS) just turned a courtroom drama into a growth story and its stock has flown +40% higher today, and a little-known insulin pump maker may be quietly scripting the sequel in metabolic health.
Hims & Hers: From GLP-1 Outlaw…
The U.S. Food and Drug Administration (FDA) is reportedly rolling out a new cash‑bonus program to reward drug reviewers who deliver high‑quality decisions ahead of schedule, a move pitched as both a modernization of government HR and a lifeline for an agency…
Oracle’s (ORCL) latest round of layoffs is less a retreat than a high‑stakes reshuffling for the age of artificial intelligence, as the software giant trades payroll for power plants in a bid to secure its place in the cloud big leagues.
A…
In the end, it was not a jury but a checkbook that settled one of biotech’s more closely watched intellectual-property dramas. Moderna will pay up to 2.25 billion dollars to Genevant Sciences and Arbutus Biopharma to resolve a global web of patent…
AST SpaceMobile (ASTS) is turning its long‑promised “cell tower in space” vision into a real, revenue‑generating business, and investors are finally getting numbers big enough to circle on a calendar instead of sketch on a napkin.
AST SpaceMobile’s First Big Leap:…
In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…
The new space economy is quietly adding an unexpected aisle to the drugstore: a “made‑in‑orbit” shelf where tomorrow’s pills may be grown, not in stainless-steel vats, but in microgravity factories looping Earth at Mach 25.
Yes one day, your doctor’s prescription may…
Japan is about to become one of America’s biggest energy backers, wiring in a $36 billion down payment on oil, gas and critical-minerals projects that doubles as foreign policy, industrial strategy and a not‑so‑subtle advert for tariffs as a negotiating tool. At…
McDonald’s (MCD) has handled low-carb fads, kale revolutions, and the brief reign of cauliflower rice, but its newest rival comes with a prescription label and a co-pay. GLP-1 weight-loss medicines—from injectables like Eli Lilly’s (LLY) Mounjaro and Zepbound to the next wave…
